Envudeucitinib vs TQH3906
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Envudeucitinib
Developed by Alumis and partners
NCT06586112 · Phase 3 · completed
Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT05739435 (registry estimate)
Reported efficacy
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)
Result source: NCT06586112
TQH3906
Developed by Sino Biopharmaceutical
NCT06542614 · Phase 2 · completed
This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.
Next expected readout: September 2027 · NCT07724366 (registry estimate)
Reported efficacy
Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)
Result source: NCT06542614
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Envudeucitinib | TQH3906 |
|---|---|---|
| PASI 75 | 56.4% vs 0%+56.4 vs placeboNCT056000364 other results
| —Trial running · NCT07724366 |
| PASI 90 | —Not posted · NCT06588738 | —Trial running · NCT07724366 |
| PASI 100 | —Not posted · NCT06588738 | —Trial running · NCT07724366 |
| sPGA 0/1 | 53.8% vs 7.9%+45.9 vs placeboNCT056000364 other results
| —Trial running · NCT07724366 |
| DLQI, change | —Not posted · NCT06588738 | —Trial running · NCT07724366 |
PASI 75
- Envudeucitinib
- 56.4% vs 0%+56.4 vs placeboNCT05600036
4 other results
- 64.1% vs 0% NCT05600036
- 33.3% vs 0% NCT05600036
- 56.4% vs 0% NCT05600036
- 19.4% vs 0% NCT05600036
- TQH3906
- —Trial running · NCT07724366
PASI 90
- Envudeucitinib
- —Not posted · NCT06588738
- TQH3906
- —Trial running · NCT07724366
PASI 100
- Envudeucitinib
- —Not posted · NCT06588738
- TQH3906
- —Trial running · NCT07724366
sPGA 0/1
- Envudeucitinib
- 53.8% vs 7.9%+45.9 vs placeboNCT05600036
4 other results
- 59% vs 7.9% NCT05600036
- 38.9% vs 7.9% NCT05600036
- 48.7% vs 7.9% NCT05600036
- 16.7% vs 7.9% NCT05600036
- TQH3906
- —Trial running · NCT07724366
DLQI, change
- Envudeucitinib
- —Not posted · NCT06588738
- TQH3906
- —Trial running · NCT07724366
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Envudeucitinib: 4 of 4 rows · TQH3906: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Envudeucitinib |
|---|---|
| Dropout rate | 10.3%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results15.4%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.5%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 16.7%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 5.6%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.7%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 2.8%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40mg BIDa headache 7.7% (placebo 5.3%) nasopharyngitis 7.7% (placebo 7.9%) upper respiratory tract infection 7.7% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results40mg QD headache 10.3% (placebo 5.3%) acne 5.1% (placebo 0%) upper respiratory tract infection 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg BID headache 7.7% (placebo 5.3%) cough 5.1% (placebo 0%) diarrhea 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg QD headache 5.6% (placebo 5.3%) upper respiratory tract infection 5.6% (placebo 0%) acne 0% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 10mg QD diabetes mellitus 5.6% (placebo 0%) nasopharyngitis 5.6% (placebo 7.9%) upper respiratory tract infection 5.6% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Envudeucitinib
show 4 more results
show 4 more results
Systemic Lupus Erythematosus
Shared mechanism: TYK2 · full Systemic Lupus Erythematosus pipeline
Envudeucitinib
Developed by Alumis and partners
NCT05966480 · Phase 2 · active, not recruiting
The trial was well designed -- randomized, triple-blinded, placebo-controlled, and adequately sized (n=408) with a recognized disease-activity measure (BICLA) as its primary endpoint -- but the overall primary comparison did not reach statistical significance. A positive signal in one prespecified subgroup does not change the fact that the main, prespecified population analysis missed, so this remains solid but inconclusive evidence rather than strong evidence of a benefit.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). (missed)
Result source: NCT05966480
TQH3906
Developed by Sino Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT07509892 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Systemic Lupus Erythematosus
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Envudeucitinib | TQH3906 |
|---|---|---|
| SRI-4 | —Not reported | —Not reported |
| BICLA | —Not reported | —Not reported |
| CLASI-50 | —Not reported | —Not reported |
| Steroid sparing | —Not reported | —Not reported |
SRI-4
- Envudeucitinib
- —Not reported
- TQH3906
- —Not reported
BICLA
- Envudeucitinib
- —Not reported
- TQH3906
- —Not reported
CLASI-50
- Envudeucitinib
- —Not reported
- TQH3906
- —Not reported
Steroid sparing
- Envudeucitinib
- —Not reported
- TQH3906
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
TQH3906: no structured comparison results are available for Systemic Lupus Erythematosus.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · TQH3906's landscape